Cargando…
A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Determine the Effect of Romiplostim on Health‐Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents
BACKGROUND: Chronic immune thrombocytopenia (ITP) in children can negatively impact their health‐related quality of life (HRQoL) and impose a burden on their parents. This study sought to examine the effect of romiplostim on HRQoL and parental burden in children with primary ITP. PROCEDURE: This was...
Autores principales: | Mathias, Susan D., Li, Xiaoyan, Eisen, Melissa, Carpenter, Nancy, Crosby, Ross D., Blanchette, Victor S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071741/ https://www.ncbi.nlm.nih.gov/pubmed/27037553 http://dx.doi.org/10.1002/pbc.25984 |
Ejemplares similares
-
Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia
por: Tarantino, Michael D., et al.
Publicado: (2019) -
Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2017) -
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
por: Soff, Gerald A., et al.
Publicado: (2019) -
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia
por: Giagounidis, Aristoteles, et al.
Publicado: (2014) -
Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022)